Long
Updated

VIRX - Bollinger Breakout with Volume

242
Viracta (VIRX) is a clinical stage biotech firm focused on the treatment of Epstein-Barr related cancers which is one of the most common virus infections found in humans. Had a good run last week, and one of those stocks that can really move with some good news. Might be worth a look.
Note
Stock popped 10% the next day before getting stopped out on a big drop. I traded in an out a couple of times as it was recovering but kept getting stopped out on all the volatility. Would have been a nice 80% run for anyone who did capture the move off the bottom. Big green volume candle on the most recent day so keeping an eye on it again.

snapshot

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.